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Infant HIV testing at birth using point-ofcare and conventional HIV DNA PCR: an
implementation feasibility pilot study in
Kenya
Matthew R. Sandbulte1, Brad J. Gautney2, May Maloba3, Catherine Wexler1, Melinda Brown1, Natabhona Mabachi1,
Kathy Goggin4,5, Raphael Lwembe6, Niaman Nazir7, Thomas A. Odeny5,8 and Sarah Finocchario-Kessler1*

Abstract
Background: Infant HIV diagnosis by HIV DNA polymerase chain reaction (PCR) testing at the standard 6 weeks of
age is often late to mitigate the mortality peak that occurs in HIV positive infants’ first 2–3 months of life. Kenya
recently revised their early infant diagnosis (EID) guidelines to include HIV DNA PCR testing at birth (pilot only),
6 weeks, 6 months, and 12 months postnatal and a final 18-month antibody test. The World Health Organization
(WHO) approved point-of-care (POC) diagnostic platforms for infant HIV testing in resource-limited countries that
could simplify logistics and expedite infant diagnosis. Sustainable scale-up and optimal utility in Kenya and other
high-prevalence countries depend on robust implementation studies in diverse clinical settings.
Methods: We will pilot the implementation of birth testing by HIV DNA PCR, as well as two POC testing systems
(Xpert HIV-1 Qual [Xpert] and Alere q HIV-1/2 Detect [Alere q]), on specimens collected from Kenyan infants at birth
(0 to 2 weeks) and 6 weeks (4 to < 24 weeks) postnatal. The formative phase will inform optimal implementation of
birth testing and two POC testing technologies. Qualitative interviews with stakeholders (providers, parents of HIVexposed infants, and community members) will assess attitudes, barriers, and recommendations to optimize
implementation at their respective sites. A non-blinded pilot study at four Kenyan hospitals (n = 2 Xpert, n = 2 Alere
q platforms) will evaluate infant HIV POC testing compared with standard of care HIV DNA PCR testing in both the
birth and 6-week windows. Objectives of the pilot are to assess uptake, efficiency, quality, implementation variables,
user experiences of birth testing with both POC testing systems or with HIV DNA PCR, and costs.
Discussion: This study will generate data on the clinical impact and feasibility of adding HIV testing at birth
utilizing POC and traditional PCR HIV testing strategies in resource-limited settings. Data from this pilot will inform
the optimal implementation of Kenya’s birth testing guidelines and of POC testing systems for the improvement of
EID outcomes.
Trial registration: ClinicalTrials.gov, NCT03435887. Registered 26 February 2018.
Keywords: HIV, Early infant diagnosis, Point-of-care testing, Birth testing, Implementation
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Background
In 2015, an estimated 110,000 new pediatric human immunodeficiency virus (HIV) infections occurred in the 21
Global Plan priority countries [1]. Infant survival and the
success of antiretroviral therapy (ART) treatment of
HIV-positive infants are associated with early infant age at
initiation [2]; thus, early HIV testing, diagnosis, and prompt
ART initiation are crucial. In 2015, an estimated 6600 children were infected with HIV in Kenya, a 55% decrease since
2009, but the country’s rate of HIV-exposed infants receiving
a routine HIV DNA polymerase chain reaction (PCR) test by
2 months of age has stagnated near 50% since 2011 [3, 4].
One barrier to successful early infant diagnosis (EID)
is the waiting time for test results. The sequence of EID
services involves multiple time-sensitive steps requiring
coordination between medical provider, diagnostic laboratory, and mother/caregiver (“mother”). The standard
EID algorithm in Kenya includes mother acceptance of
infant testing; specimen collection, transport, and laboratory analysis; communication of results to healthcare providers and caregivers; and linkage to care,
including opportunistic infection prophylaxis for all
HIV-exposed infants and ART for HIV-positive infants
[5]. All steps are susceptible to delays and patient loss to
follow-up [5–7]. Traveling long distances for clinical
care adds logistical and resource barriers to successful
HIV treatment [8].
Innovative strategies with potential to accelerate the
delivery of appropriate care to HIV-exposed infants include launching EID at birth rather than the standard
6 weeks of age and streamlining the EID cascade [9].
While these approaches are promising, resource constraints for all stakeholders in EID services (e.g., providers, laboratories, and mothers) require consideration.
Adding a testing time point at or near birth, with
standard-of-care (SOC) or point-of-care (POC) technology, would likely require more clinical and laboratory
workload and equipment capacity [10], and potentially
more travel to the clinic by mothers and infants. Conventional testing of HIV-exposed infants has not been
initiated until 6 weeks of age because DNA PCR test
sensitivity is lower in newborns and neonates (68% and
88% at birth and 4 weeks [11]), intrapartum (IP) HIV infections are not detectable immediately after birth, and
the 6-week time point coincides with immunization
visits. HIV-infected infants first tested around 6 weeks
often are initiated on ART at median ages of 16.0 to
24.5 weeks [12–15], which is too late to mitigate the
early peak in mortality around 8–12 weeks of age [16].
In Kenya, 61% of pregnant women deliver in a health care
facility and 20% of the infants delivered at home receive a
postnatal checkup within 1 week of birth [17]; therefore,
testing performed at birth or first clinical contact could accelerate ART initiation in HIV intrauterine-infected infants.
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Recent recommendations by the WHO and the Kenya
Ministry of Health [18, 19] reflect a consensus that birth
HIV testing could improve outcomes for HIV-infected infants, even with lower test sensitivity on newborn samples
[20, 21]. Kenya’s guidelines call for piloting birth HIV DNA
PCR testing of HIV-exposed infants, in addition to further
HIV DNA PCR tests at 6 weeks, 6 months, and 12 months.
However, pilot data for birth testing (0–2 weeks) is needed
prior to national rollout.
In 2016, the WHO prequalified two point-of-care
(POC) diagnostic tests for detection of HIV RNA in
whole blood samples (Xpert HIV-1 Qual for GeneXpert
instruments, manufactured by Cepheid AB; Alere q
HIV-1/2 Detect manufactured by Abbott). Both tests are
cartridge-based, real-time reverse transcription PCR
qualitative assays performed with benchtop instruments
that are suitable for operation in the clinic setting and
do not require extensive technical training [22, 23]. The
initial published evaluations of the Xpert HIV-1 Qual or
Alere q HIV-1/2 tests performance were conducted by
diagnosticians in the laboratory setting [22–25], showing
good sensitivity (93.3–98.7%) and specificity (100%) with
infant samples. By definition, the POC test systems provide optimum value in expediting EID if they are performed in the clinic setting, by clinical personnel. Field
studies of both the Xpert HIV-1 Qual [26, 27] and Alere
q HIV-1/2 [27–29] were performed in clinical care facilities, by medical caregivers. Sensitivity and specificity
values were similar to those reported from the
laboratory-based qualification studies, but in some instances the field studies produced higher rates of test
error [26, 29]. Recent studies with large numbers of
HIV-positive newborn infants show close concordance
between SOC tests and both of these POC technologies
[26, 27]. While analytic performance profiles of these
POC technologies have been characterized in field
studies, sustainable scale-up and optimal utility in Kenya
and other resource-constrained countries requires robust implementation studies in diverse clinical settings.
Currently, there is a lack of data to guide strategic implementation of the birth testing timepoint or the Xpert
and Alere q POC testing platforms in Kenya. Here, we
report the protocol for a pilot study to assess feasibility
and preliminary impact of introducing birth testing as
an addition to EID services, and to evaluate the two
POC platforms in parallel with laboratory-based HIV
DNA PCR.

Objectives

1. Assess acceptability and uptake of birth testing and
both prequalified POC testing platforms in Kenyan
clinical settings.
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2. Collect pilot data quantifying the efficiency and
completeness of EID services augmented with birth
and POC testing.
3. Capture pilot data tracking the reliability/
performance of both POC platforms for EID
services.
4. Engage EID providers in interviews to assess user
satisfaction with birth and POC testing and gather
feedback on implementation barriers and
facilitators.
5. Compute costs of implementing POC testing
platforms to fulfill Kenyan EID guidelines.

Methods
Study design

In this feasibility study, the new birth EID testing timepoint and two POC infant diagnostic platforms will be
implemented on a pilot scale in Kenya. Xpert and Alere
q HIV POC platforms will be introduced at four Kenyan
government hospitals, for birth and 6-week testing time
points. This 18-month study was initiated as a supplement to a parent study (R01HD076673) implementing
and evaluating the HIV infant tracking system (HITSystem) [30]. The four hospitals designated as study sites
are government hospitals with medium to high patient
volume, and geographic variation: two in Kisumu
County, one in Nakuru County, and one in Mombasa
County. Estimated rates of mother to child transmission
of HIV in these three counties in 2015 were 20%, 5%,
and 18%, respectively [31]. Phase 1 is a 6-month formative phase in which we will conduct qualitative interviews with parents, providers, and community members
to assess stakeholder attitudes toward birth and POC
testing and barriers to acceptance or uptake. Feedback
will be used to refine operational plans with regard to
feasibility and acceptability. Phase 2 is a 12-month feasibility pilot of the two new POC testing strategies. The
12-month implementation period allows time for providers to adopt the new practices and to monitor any
fluctuations in uptake or acceptability during this extended period. POC HIV testing will be conducted in
parallel with standard laboratory-based HIV DNA PCR,
targeting sample collection at birth (0 to 2 weeks) and at
6 weeks (4 to < 24 weeks).
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disclosed HIV status, n = 10 per site) will focus on the
impact for the infant and family (confidentiality/disclosure, acceptability of timing of testing and results, and
partner support). Interviews with providers who would
be involved with POC testing at each site (PMTCT, maternity, and maternal and child health (MCH) nurses;
mentor mothers; laboratory technicians; and ART clinicians; approximately n = 5 per site) will highlight issues
of training, site-specific logistics, patient preparation and
counseling, and personnel and resource considerations
for implementation. We will also conduct interviews
with community members (community health workers,
traditional birth attendants, and respected community
and religious leaders; approximately n = 10 per site) in
one rural community within the catchment area of each
hospital to elicit attitudes and suggestions regarding the
potential for periodic POC HIV testing in hard to access
communities. Informed consent will be obtained prior to
conducting the interviews in a private setting. Participants will receive 500 Kenyan Shillings (approximately
USD $5.00) to compensate for travel and time.
Analysis

Interviews will be audio recorded for subsequent transcription, translation, coding, and analysis. Transcripts
will be coded independently by two study team members
to identify a priori and emergent themes. Discrepancies
in coding will be resolved by group consensus. We will
develop a codebook with typical exemplars for each
theme, noting the frequency and distribution of themes
within the larger topic areas. The study team will review
themes to inform the POC pilot (phase 2).
Phase 2: intervention
Study design

We will pilot the implementation of POC and birth testing at four government hospitals over a 12 month
period. The four study sites will be randomized, using a
random number generator, to pilot one of the two POC
systems (Xpert HIV-1 Qual for HIV RNA or Alere q
HIV-1/2 Detect). SOC diagnostic testing (HIV DNA
PCR test on DBS samples) will be conducted in parallel
at all study sites, including the newly introduced birth
testing time point. Patient flow in the pilot is diagrammed in Fig. 1.

Phase 1: formative research

Phase 1 seeks to gain information from key stakeholders
that will guide operational planning to optimize uptake,
acceptability, and feasibility of services at each study site.
Approximately n = 25 formative interviews with parents,
providers, and community members will be conducted
at each site; 100 interviews total. Interviews with parents
(HIV-positive mothers with prior EID experience and
their male partners if available and mother has already

Participant recruitment, eligibility, and consent

HIV-positive pregnant women or mothers of HIV-exposed infants engaged in care at study hospitals will be
invited to participate in the pilot. Women can be enrolled either through PMTCT, during pregnancy;
through maternity, at delivery; or through the MCH department, at their first postnatal infant visit. Women
must be at least 18 years of age and their HIV-exposed
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Fig. 1 Patient flow during evaluation of infant HIV testing strategies. The study will track engagement of enrolled mother-infant pairs in
point-of-care (POC) and standard of care HIV DNA polymerase chain reaction (PCR) test technologies through the birth and 6-week
testing windows

infant less than 24 weeks of age to be eligible for the study.
Pregnant women/mothers will be informed by trained research or clinical staff of the purpose of the research, the
potential benefits, and the risks. They will also be counseled on expectations for POC testing at the time of delivery or within 2 weeks if delivery does not occur in the
hospital, and the importance of returning for the birth
PCR results and retesting at 6 weeks. Those agreeing to
participate will provide written informed consent prior to
enrollment in the study (Additional file 1). Clinical staff
will promote participant retention and complete
follow-up by continued outreach to enrolled mothers at
ANC and MCH appointments. Infants of mothers who
decline participation in the study will receive the on-site
standard of care (SOC) EID (laboratory-based HIV
DNA PCR testing at 6 weeks). The study protocol complies with the Helsinki Declaration and was reviewed
and approved by the Institutional Review Boards at the
Kenya Medical Research Institute (protocol KEMRI/
SERU/CVR/018/3390) and the University of Kansas
Medical Center (protocol # 00140399). A data monitoring committee was not required because the
interventions are minimally invasive diagnostic strategies posing no elevated risks of severe outcomes.
Protocol modifications will be communicated to facility
personnel by research team site coordinators.
Pilot POC intervention

Personnel training Study staff will be trained in procedures for informed consent and study enrollment and
the protection of patient confidentiality. The hospital
maternity staff will be trained to conduct a heel stick
and collect two samples at each time point (DBS and

whole blood). A half-day of training will be provided to
EID staff on the equipment, cartridges, and procedures
used to conduct POC tests at their hospital. Study coordinators at each site will arrange periodic refresher training
and new personnel training as rotation of staff occurs.
Birth testing For all infants presenting for birth testing
(within 2 weeks of age), the designated staff at each facility will collect two blood samples. A whole blood sample
for POC testing (Xpert HIV-1 Qual or Alere q HIV-1/2
Detect) will be processed on-site by healthcare providers
using test cartridges and POC machine. POC test results
will be recorded in study logs and printout results from
each of the POC machines will be attached to the infant’s clinical file (see Data collection, below). Mothers
will be notified of the POC test result on the same day
as testing or before infant’s hospital discharge (within
24 h). The second sample will follow the established
SOC procedures for HIV DNA PCR testing: a dried
blood spot (DBS) sample will be sent by courier to the
hospital’s designated central laboratory for standard HIV
DNA PCR. Results of HIV DNA PCR processed in the
central laboratory will be recorded on paper forms and
returned to the hospital by courier service. When the
HIV DNA PCR result is received at the hospital, the
mother will be called to return for result notification
and counseling. If the infant has an HIV-positive test result (by either POC or PCR), the mother and infant will
be linked to the Comprehensive Care Center (CCC) for
same-day ART initiation. HIV-positive infants identified
through this study will receive additional clinical monitoring (ART adherence, viral suppression, and immune system strength) through 24 months of age. HIV-negative
infants will be scheduled to return to the hospital for
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six-week postnatal appointments and repeat HIV testing
(HIV DNA PCR and POC).
Six-week testing All infants who present for care at 4
to < 24 weeks of age, not previously diagnosed HIV-positive,
will be eligible for 6-week testing. The same sequence of
DBS and whole blood sample collection, DBS shipment for
processing off-site, POC processing in clinic, result notification, and ART initiation (for HIV-positive infants) will be
conducted as at birth. The optimal test sequence of an
HIV-negative infant will be complete when HIV results at
birth and 6 weeks postnatal have been provided to mothers.
Discordant results In the case of discordant POC/HIV
DNA PCR test results at birth or at 6-weeks, the infant
will be initiated on ART based on the positive result
from either method. A second, confirmatory sample will
be collected and processed using both the POC and HIV
DNA PCR procedures. A third sample will also be sent
to the national reference lab for HIV DNA PCR processing. The infant will continue on ART until the results of
the HIV DNA PCR test and the National Reference Lab
results are available. ART continuation will be based on
the HIV DNA PCR results.
ART adherence monitoring of HIV-positive infants In
order to monitor ART adherence and viral suppression, we will order quarterly CD4 and viral load (VL)
tests for all HIV-positive infants until 24 months of
age. At each time point, mothers of HIV-positive infants will take a brief survey, administered by the
pediatric ART provider, regarding ART adherence and
side effects. Since we anticipate that infants will be
started on ART significantly earlier than in SOC, this
increased monitoring is intended to characterize infants’ virologic and immunologic responses to early
treatment, providing preliminary data to inform design of a larger-scale randomized trial.
Data collection Using Epi Info software (US Centers for
Disease Control and Prevention), site coordinators will
collect and maintain a comprehensive electronic record
of each infant’s relevant clinical data including date of
birth, location of birth, POC sample collection and processing dates, POC test results, POC result notification
to mothers, dates of SOC sample collection and return
of results to the hospital, results of HIV DNA PCR test,
mother notification of HIV DNA PCR results, and date
of initiation of HIV-positive infants on ART. To ensure
complete and accurate clinical data entry, site coordinators will periodically cross-check Epi Info files with various clinical records including ANC registers, maternity
records, HIV-exposed infant registers, mother and infant
clinical files, and hard copies of laboratory diagnostic
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results. Data pertaining specifically to treatment of
HIV-positive infants (including ART initiation, OI
prophylaxis, and viral load and CD4 monitoring through
24 months) will be accessed from HIV exposed infant
registers, CCC records, and infant clinical files.
Study-specific data collection logs will track enrollment across varying departments, reasons for enrollment
refusal, use of the POC machines including dates and
times of sample collection and processing and the
personnel processing the test, POC machine errors and
their effect on clinical care, adverse events that occur as
a result of the study, communication between clinical or
study staff and participants, and hospital or
national-level events that may impact clinical care and
study operations. These logs will help gauge implementation feasibility and provider experience. The principle
investigator and IRB-certified research staff will have access to the final trial dataset, with no contractual
hindrances.
Experience of providers Qualitative data will be collected on providers’ implementation experience. The
study site coordinator at each hospital will conduct
monthly meetings including department heads (PMTCT,
Maternity, MCH, Laboratory, Outpatient Department,
and CCC) and all providers engaged in study implementation. While meeting guides were developed using the
Consolidated Framework for Implementation Research
(CFIR) as a guide [32], questions will vary to ensure responsiveness to provider concerns and challenges
expressed at different stages of the study. Topics of these
discussions will include training and sensitization of
personnel; stakeholder coordination; sensitization, enrollment, and satisfaction of mothers; deployment of
POC testing; workflow optimization; management of the
test cartridge supply stream; technical challenges; and
context-specific solutions. The study team will review
themes after each meeting to inform any required modifications to POC implementation (phase 2). Participants
will complete an informed consent at the first meeting
for permission to audio record the sessions for later
transcription and analysis of the implementation experiences at each hospital.
Calculating costs of POC Costs associated with each
POC strategy will be collected and compared to the
existing EID testing process. We will estimate costs from
a donor or government perspective to calculate and
compute costs of integrating each POC strategy into an
existing system compared to HIV DNA PCR processed
at central laboratories, the current gold standard for EID
care. We will use standard procedures for intervention
cost estimation [33].
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Fidelity assurance procedures

Standard operating procedures (SOPs) were developed
to standardize training, enrollment, and data collection.
Personnel will be trained on the SOPs, which will be
kept available at each site for convenient reference.
Study management will provide supportive supervision
visits quarterly to assess protocol adherence. The objectives of these visits include overseeing and assisting with
formative interviews with key stakeholders, providing
site-level training on study protocols to clinical and
study staff, review of consent forms, and discussion of
any challenges with the study team. Technical competence and compliance with POC SOPs will be evaluated
by a checklist that includes maintenance of workspace,
blood collection technique, operation of the machine,
cartridge-loading technique, following machine prompts
through to result reporting and archiving, biosafety and
waste disposal procedures, and test documentation. Furthermore, the study team will hold a bi-weekly study call
to update enrollment numbers, review study logs, and
address any challenges or concerns with the consent
process or study implementation. Site coordinators are
required to report any adverse event immediately to the
US- and Kenya-based principle investigators. Adverse
events would include unintentional disclosure of HIV
status or emotional distress related to study participation. Infant death is a non-study-related adverse event
also reported to the IRB.
Performance and reliability of the POC tests will be
monitored by sending every tenth specimen to the national reference laboratory for confirmatory testing by
HIV DNA PCR. By agreement with the national POC
technical working group, each infant sample with an
HIV-positive POC or HIV DNA PCR test result will be
followed up by collection of a second sample for confirmatory testing at the national reference laboratory.
Confidentiality

Study staff will be trained on the protection of patient
confidentiality. Prior to the study, study site coordinators
will meet with clinic staff and peer counselors to identify
additional strategies appropriate to the local setting to
improve participant confidentiality. Access to electronic
data will be restricted to research staff directly involved
in implementation and evaluation of the pilot. All electronic data will be de-identified and recorded through
use of an identification number for each HIV-positive
woman and her HIV-exposed infant. The link between
participant name and identification number is known
only by the site coordinator who conducts enrollment
and by the provider who has an established care relationship with the participant. The record linking patient
name and electronic ID will be securely stored in a
locked office. De-identified data will be used for all

Page 6 of 10

analyses and results will be reported as aggregates and
ratios.
Study outcomes

Acceptability and uptake Key informant interviews will
document attitudes, preferences, perceived benefits, and
concerns from the perspective of stakeholders (HIV-positive mothers, EID providers, community members)
(Table 1). Uptake of testing, by POC and SOC methods,
will be quantified in terms of proportions of infants who
are tested (have a documented specimen collection) in
the birth and 6-week windows and the proportion of infants determined HIV-negative at birth who are presented again for retesting in the 6-week window.
Infant testing outcomes The completeness and efficiency of fulfillment of Kenyan EID testing guidelines
upon implementation of birth and POC testing at study
sites will be measured (Table 1). Measures of completeness will include proportions of birth and 6-week tests
with results returned and with mothers notified of results. Additionally, we will track “complete retention,”
the proportion of mothers who are notified of results
from specimens collected in both the birth and 6-week
windows. Measures of efficiency include turnaround
time (TAT) associated with key steps in POC or HIV
DNA PCR-based diagnosis: TAT from specimen collection to result availability, TAT from result availability to
mother notification of results, and overall TAT from specimen collection to mother notification. Infant age at
completion of each step of diagnosis (and at ART initiation if testing HIV-positive) will be further measures of
EID efficiency that imply clinical timeliness of the specific EID steps.
POC platform performance Assessment of both the
Xpert and Alere q HIV POC platforms will include
evaluation of testing reliability (Table 1). Measures to be
tracked include number of failed tests (and wasted cartridges), and number of missed opportunities to engage
infants with POC testing due to documented machine
breakdown, machine error, or cartridge stockout. The
anticipated number of HIV-positive infants identified is
too small to support robust sensitivity or specificity calculations, but we will track concordance between test results from each POC platform and the corresponding
HIV DNA PCR results.
EID provider feedback Provider interviews conducted
during the pilot study will solicit provider feedback on
challenges faced in implementing birth and POC testing,
including matters of personnel training, optimizing
workflow, engagement of mothers, management of
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Table 1 Implementation and feasibility measures
Variable

Measure (for both POC and HIV DNA PCR tests, unless specified)

Acceptability/uptake

Mothers’ views of birth testing impact on infant, family

EID stage(s)

Provider recommendations/concerns on implementation
Community member attitudes and recommendations

Infant testing outcomes

POC platform performance

Provider feedback

Proportion (%) infants with specimen collected

Birth, 6 weeksa

Median infant age at specimen collection

Birth, 6 weeks

% Birth-tested infants returned for 6-week retest

Sequential

% Tests with results returned

Birth, 6 weeks

% Tests with mother notified of results

Birth, 6 weeks

Median turn-around time (TAT), specimen to test result availability

Birth, 6 weeks

Median infant age at result availability

Birth, 6 weeks

Median TAT, result availability to mother notification of results

Birth, 6 weeks

Median overall TAT, specimen to mother notification of results

Birth, 6 weeks

Median infant age at mother notification of results

Birth, 6 weeks

Median infant age at ART initiation (if diagnosed HIV+)

Birth, 6 weeks

Complete retention: % mothers notified of birth AND 6-week results

Sequential

Number failed POC tests, GeneXpert and Alere q

Pooled

Number POC missed opportunities due to machine breakdown

Pooled

Number POC missed opportunities due to machine error

Pooled

Number POC missed opportunities due to cartridge stockout

Pooled

Concordance of POC results (each platform) with HIV DNA PCR

Birth, 6 weeks

Acceptability and feasibility of implementing birth and POC testing
Benefits and challenges of birth and POC testing for patients

Costs of POC implementation

Acquisition of GeneXpert and Alere q machines
Acquisition of accessory equipment
Site-specific training, secure storage
Acquisition of test cartridges
Maintenance and repair of machines

Birth testing is denoted when specimen is collected at 0–2 weeks of age. “Six-week” testing is denoted when specimen is collected at 4 to < 24 weeks of age

a

cartridge supply, and technical challenges. Providers’
views of the benefits and risks of birth and POC testing
for patients will be recorded.
Costs of POC testing implementation Cost measures
to be tracked and analyzed for each of the POC test platforms include up-front purchase of machines and
accessory equipment; site-specific training and secure
equipment storage; purchase of test cartridges, including
delivery and customs fees; and machine repair.
Statistical analysis

This study is designed to gather preliminary outcome
data to inform implementation guidance and pilot
data for a subsequent larger study. We anticipate
mean monthly enrollment per study site of approximately 15 eligible participants, yielding an estimated

total enrollment of 720 mother-infant pairs by the
end of the 12-month intervention phase. Reductions
in study participation are expected to result from
documented transfer to other facilities, loss to follow-up,
miscarriage, and infant mortality prior to testing.
Nonetheless, we anticipate ample power to describe and
compare outcomes of birth testing and between POC and
PCR testing strategies to estimate effect sizes and an
intracluster correlation coefficient (ICC) to inform future
sample size and power calculations.
Categorical variables will be presented as proportions,
and continuous variables as means (SD) or medians
(IQR) depending on the distribution of data. Quantitative measures compared across POC platforms or between POC and HIV DNA PCR testing methods will be
analyzed using parametric and non-parametric (Exact or
Wilcox and Rank-sum) tests.
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Study status

We have conducted formative interviews with stakeholders (providers, HIV-positive parents, and community members). We began mother-infant enrollment in
the study in June of 2017. During the initial 6 months,
participant enrollment and full implementation of the
pilot were limited by external challenges (prolonged national nurses’ strike and Alere q manufacturer’s cartridge
stock-out), which were resolved, setting the stage for
normal operations. Participant enrollment is ongoing
and expected to conclude in December 2018. We plan
to report study results to a national technical working
group on implementation of birth and POC testing in
Kenya, to the Ministry of Health, and to administrators
of the participating facilities. Data will be published in
peer-reviewed scientific journals.

Discussion
The effectiveness of ART in HIV-infected infants is optimal when HIV is diagnosed early, so that treatment can
be initiated before a peak in mortality observed between
2 and 3 months [16]. For this reason, Kenyan government guidance issued in 2016 recommends adding birth
HIV DNA PCR testing to the standard regimen of PCR
tests at 6 weeks, 6 months, and 12 months [19]. However, to date, this is only a provisional recommendation
pending pilot data to inform national scale-up. This
study will contribute needed pilot data to inform decision making for birth testing with traditional HIV DNA
PCR or with POC strategies. Notably, recent data from
South Africa suggest uptake of repeat testing at 6 or
10 weeks of age may be diminished among infants
already diagnosed HIV-negative at birth [34]. A reduction in retesting rates compromises detection of intrapartum transmissions, thus the impact of birth testing
on repeated testing at 6 weeks is an important concern
for governments considering policy changes. In addition
to assessing uptake and acceptability of the new testing
time point and testing strategy (POC), this pilot and
feasibility study is designed to assess retest rates for infants tested within the birth window to better understand implications for the Kenyan context.
POC testing also offers potential to improve EID system efficiency in low resource settings where there are
multiple delays inherent in the laboratory-based HIV
DNA PCR testing process. Sample testing in the clinic
setting potentially facilitates mother notification of infant
HIV status on the same day as test. To fully realize the
POC technology’s potential at the true point of care,
cadres of clinical providers must be trained to perform
diagnostic procedures outside of traditional clinical duties. Therefore, in addition to traditional laboratory
personnel, our pilot study includes training nurses to
conduct POC testing within the Maternity and MCH
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settings. This pilot will solicit provider feedback regarding issues of patient flow, interdepartmental collaboration, and provider workload, while identifying potential
barriers to this task-shifting approach during larger
scale-up. Other performance measures reflecting the
utility of POC platforms—such as user friendliness,
equipment durability, test failure rate, costs of maintenance, and frequency of cartridge stockouts—will likely
affect the consistency of testing operations and missed
opportunities for diagnosis. This pilot study will track
these variables and thus supply preliminary feasibility
data to inform effective and sustainable POC interventions for larger future studies.
These novel data on implementation outcomes and
clinical impact of birth HIV testing with POC and PCR
testing strategies are timely given the movement toward
more rigorous EID in low resource countries. Implementation and user satisfaction data from the two approved
POC platforms, GeneXpert and Alere q, may also guide
other groups considering investment in POC scale-up.
By providing parameters to estimate effect size and
intraclass correlation, these results will facilitate the design of properly powered pragmatic trials to evaluate the
impact of birth and POC HIV testing in Kenya. These
timely data may also facilitate wider adoption of 2016
EID guidelines issued by WHO and the government of
Kenya to accelerate infant testing within the existing
PCR infrastructure, while bridging the birth testing strategy to implementation of POC testing technologies.
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Additional file 1: Written informed consent: point-of-care testing enrollment. (PDF 49 kb)
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